Y 9000

Y 9000 (5-50 mg/kg; p.o.; single dose 1 hour pre-antigen; 0.5-50 mg/kg; i.p.; single dose 30 minutes pre-antigen) inhibits IgE-mediated 48-hour homologous PCA in rats in a dose-dependent manner, with an oral ED₅₀ of 11 mg/kg for egg albumin-induced PCA and intraperitoneal ED₅₀ of 2.7 mg/kg^[1].
Y 9000 (50-250 mg/kg; p.o.; single dose 1 hour pre-antigen; 5-100 mg/kg; i.p.; single dose 30 minutes pre-antigen; 25-100 mg/kg; p.o.; single dose 1 hour pre-antigen in adrenalectomized rats) inhibits IgG-mediated 4-hour heterologous PCA in intact rats in a dose-dependent manner, with an oral ED₅₀ of 75 mg/kg and intraperitoneal ED₅₀ of 14 mg/kg, and this inhibitory effect is reduced in adrenalectomized rats^[1].
Y 9000 (5-25 mg/kg; i.p.; single dose 30 minutes pre-antigen; 100 mg/kg; p.o.; single dose 2 hours pre-antigen) inhibits IgE-mediated active anaphylactic bronchoconstriction in sensitized rats in a dose-dependent manner via intraperitoneal and oral routes^[1].
Y 9000 (25-100 mg/kg; i.p.; single dose 30 minutes pre-aerosol challenge) inhibits IgG-mediated anaphylactic asthma in passively sensitized guinea pigs via intraperitoneal administration, with an ED₅₀ of 50 mg/kg^[1].
Y 9000 (100-500 mg/kg; p.o.; single dose 1 hour pre-antigen; 10-100 mg/kg; i.p.; single dose 30 minutes pre-antigen) dose-dependently protects against active systemic anaphylaxis in sensitized mice, with an oral ED₅₀ of ~250 mg/kg and intraperitoneal ED₅₀ of 50 mg/kg^[1].
Y 9000 (2.5-25 mg/kg; p.o.; single dose 1 hour pre-induction; 0.5-10 mg/kg; i.p.; single dose 30 minutes pre-induction) inhibits egg albumin-induced anaphylactoid reactions in rats in a dose-dependent manner via oral and intraperitoneal routes, with an oral ED₅₀ of 4 mg/kg and intraperitoneal ED₅₀ of 1 mg/kg^[1].